Patheon will showcase its biologic, small molecule API development services, and manufacturing capabilities for finished dosage forms at CPhI/ICSE Worldwide.
Patheon (booth 1H9) will showcase its biologic, small molecule API development services, and manufacturing capabilities for finished dosage forms at CPhI/ICSE Worldwide from Tuesday, Oct. 7, to Thursday, Oct. 9, in Paris Nord Villepinte, France.
The company will also introduce its new end-to-end development offering, OneSource, which now provides a single, seamless solution to customers for Phase I through Phase II projects, delivering a simplified process for both drug substance and drug product development. With the launch of OneSource, Patheon will connect its services from drug substance to drug products, focusing on simplicity, speed and uncompromised quality. The company’s expertise in development services and large scale production will enable Patheon to integrate all utilized technologies in one, lean process, which will deliver additional customer value. The OneSource offering is led by Lukas Utiger, PhD, who will give a presentation at the Speaker’s Corner at CPhI/ICSE Worldwide on Wednesday, Oct. 8 at 2:00 p.m., for attendees who would like to find out more about Patheon’s full offerings.
“After much work, we are pleased to provide customers OneSource, which is available for Phase I through Phase II projects,” said Lukas Utiger, PhD, president, DPx Fine Chemicals (formerly DSM Fine Chemicals) and Integrated Offering, in a press statement. “We continue to streamline this offering and have future plans to provide similar simplicity to Phase III through commercial scale capabilities as well. We feel strongly that it is important to bring fast and simple solutions to our customers that really address their needs.”
Source: Patheon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.